EGFR-Thr654 and EGFR-Ser1046 phosphorylation decreased upon application of an AURKA inhibitor, but only in EGFR-L858R mutant cell lines, which raised the possibility of the therapeutic application of AURKA inhibitors in lung cancer patients. The gene discussed is EGFR; the disease is lung cancer.